相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo
Jane Renshaw et al.
CLINICAL CANCER RESEARCH (2013)
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Karen E. Sheppard et al.
EUROPEAN JOURNAL OF CANCER (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
mTOR kinase structure, mechanism and regulation
Haijuan Yang et al.
NATURE (2013)
Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells
Heloisa P. Soares et al.
PLOS ONE (2013)
Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models
Hua Zhong et al.
PLOS ONE (2013)
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma
Ryan B. Corcoran et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma
Alessandro Conti et al.
BIOMED RESEARCH INTERNATIONAL (2013)
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
E. J. Haagensen et al.
BRITISH JOURNAL OF CANCER (2012)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2012)
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi et al.
CLINICAL CANCER RESEARCH (2012)
Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
Patrick J. Roberts et al.
CLINICAL CANCER RESEARCH (2012)
The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
Bao Hoang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy
Cheng-Xiong Xu et al.
CANCER BIOLOGY & THERAPY (2011)
In Vivo Activity of Combined PI3K/mTOR and MEK Inhibition in a KrasG12D;Pten Deletion Mouse Model of Ovarian Cancer
Kathryn M. Kinross et al.
MOLECULAR CANCER THERAPEUTICS (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Genetic and Functional Studies Implicate HIF1α as a 14q Kidney Cancer Suppressor Gene
Chuan Shen et al.
CANCER DISCOVERY (2011)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
Ker Yu et al.
CANCER RESEARCH (2009)
The Pharmacology of mTOR Inhibition
David A. Guertin et al.
SCIENCE SIGNALING (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy
Xuerong Wang et al.
CANCER BIOLOGY & THERAPY (2008)
mTOR pathway in renal cell carcinoma
Sara C. Hanna et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin
NATURE REVIEWS CANCER (2008)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Molecular pathways in renal cell carcinoma- Rationate for targeted treatment
William Y. Kim et al.
SEMINARS IN ONCOLOGY (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Role of VHL gene mutation in human cancer
WY Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Inhibition of HIF2 alpha is sufficient to suppress pVHL-defective tumor growth
K Kondo et al.
PLOS BIOLOGY (2003)
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
K Kondo et al.
CANCER CELL (2002)
分享论文
